当前位置: X-MOL 学术Stem Cells Int. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Design and Optimization of the Circulatory Cell-Driven Drug Delivery Platform
Stem Cells International ( IF 4.3 ) Pub Date : 2021-09-22 , DOI: 10.1155/2021/8502021
Pengyu Gao 1 , Dan Zou 1 , Ansha Zhao 1 , Ping Yang 1
Affiliation  

Achievement of high targeting efficiency for a drug delivery system remains a challenge of tumor diagnoses and nonsurgery therapies. Although nanoparticle-based drug delivery systems have made great progress in extending circulation time, improving durability, and controlling drug release, the targeting efficiency remains low. And the development is limited to reducing side effects since overall survival rates are mostly unchanged. Therefore, great efforts have been made to explore cell-driven drug delivery systems in the tumor area. Cells, particularly those in the blood circulatory system, meet most of the demands that the nanoparticle-based delivery systems do not. These cells possess extended circulation times and innate chemomigration ability and can activate an immune response that exerts therapeutic effects. However, new challenges have emerged, such as payloads, cell function change, cargo leakage, and in situ release. Generally, employing cells from the blood circulatory system as cargo carriers has achieved great benefits and paved the way for tumor diagnosis and therapy. This review specifically covers (a) the properties of red blood cells, monocytes, macrophages, neutrophils, natural killer cells, T lymphocytes, and mesenchymal stem cells; (b) the loading strategies to balance cargo amounts and cell function balance; (c) the cascade strategies to improve cell-driven targeting delivery efficiency; and (d) the features and applications of cell membranes, artificial cells, and extracellular vesicles in cancer treatment.

中文翻译:

循环细胞驱动给药平台的设计与优化

实现药物递送系统的高靶向效率仍然是肿瘤诊断和非手术治疗的挑战。尽管基于纳米颗粒的给药系统在延长循环时间、提高耐久性和控制药物释放方面取得了很大进展,但靶向效率仍然很低。由于总体存活率几乎没有变化,因此开发仅限于减少副作用。因此,在肿瘤领域探索细胞驱动的药物递送系统已经做出了巨大努力。细胞,尤其是血液循环系统中的细胞,可以满足基于纳米颗粒的递送系统所不能满足的大部分需求。这些细胞具有延长的循环时间和先天的化学迁移能力,可以激活发挥治疗作用的免疫反应。然而,新的挑战出现了,例如有效载荷、细胞功能变化、货物泄漏和原位释放。总的来说,利用血液循环系统的细胞作为货物载体已经取得了很大的好处,为肿瘤的诊断和治疗铺平了道路。本综述特别涵盖 (a) 红细胞、单核细胞、巨噬细胞、中性粒细胞、自然杀伤细胞、T 淋巴细胞和间充质干细胞的特性;(b) 平衡货物数量和细胞功能平衡的装载策略;(c) 提高细胞驱动靶向递送效率的级联策略;(d) 细胞膜、人工细胞和细胞外囊泡在癌症治疗中的特点和应用。使用血液循环系统的细胞作为货物载体取得了巨大的好处,为肿瘤的诊断和治疗铺平了道路。本综述特别涵盖 (a) 红细胞、单核细胞、巨噬细胞、中性粒细胞、自然杀伤细胞、T 淋巴细胞和间充质干细胞的特性;(b) 平衡货物数量和细胞功能平衡的装载策略;(c) 提高细胞驱动靶向递送效率的级联策略;(d) 细胞膜、人工细胞和细胞外囊泡在癌症治疗中的特点和应用。使用血液循环系统的细胞作为货物载体取得了巨大的好处,为肿瘤的诊断和治疗铺平了道路。本综述特别涵盖 (a) 红细胞、单核细胞、巨噬细胞、中性粒细胞、自然杀伤细胞、T 淋巴细胞和间充质干细胞的特性;(b) 平衡货物数量和细胞功能平衡的装载策略;(c) 提高细胞驱动靶向递送效率的级联策略;(d) 细胞膜、人工细胞和细胞外囊泡在癌症治疗中的特点和应用。和间充质干细胞;(b) 平衡货物数量和细胞功能平衡的装载策略;(c) 提高细胞驱动靶向递送效率的级联策略;(d) 细胞膜、人工细胞和细胞外囊泡在癌症治疗中的特点和应用。和间充质干细胞;(b) 平衡货物数量和细胞功能平衡的装载策略;(c) 提高细胞驱动靶向递送效率的级联策略;(d) 细胞膜、人工细胞和细胞外囊泡在癌症治疗中的特点和应用。
更新日期:2021-09-22
down
wechat
bug